Retinitis pigmentosa is an inherited degenerative condition that destroys photoreceptors in the retina and can eventually lead to irreversible blindness. In a clinical trial first, an international research team has demonstrated that optogenetic therapy is safe to use and shows potential for restoring visual function in patients with late stages of this disorder.

In a first-in-human study in 2021, the collaboration – led by José-Alain Sahel from the University of Pittsburgh School of Medicine and Botond Roska from the Institute of Molecular and Clinical Ophthalmology Basel (IOB) – demonstrated that optogenetic therapy led to partial recovery of visual function in a blind patient with retinitis pigmentosa. This latest work, reported in the New England Journal of Medicine, expands the cohort to 10 participants.

Optogenetics is a method that uses light to characterize and manipulate the activity of neurons in the brain – and which earlier this week won its inventors the 2026 Nobel Prize in Physiology or Medicine. The optogenetic therapy developed by Sahel, Roska and collaborators combines gene therapy that makes surviving ganglion cells (neurons in the retina) sensitive to light with special goggles that stimulate the altered cells.

“Although patients with retinitis pigmentosa lose their rod and cone cells, which normally detect light, many other cells within the retina can remain present for years after vision loss,” explains Sahel, director of the UPMC Vision Institute and first author on this study. “Optogenetics enables us to introduce a light-sensitive protein into these surviving cells, allowing them to respond to light and transmit visual information to the brain. The therapy bypasses the damaged photoreceptors and takes advantage of retinal circuits that remain intact.”

Sahel notes that retinitis pigmentosa can be caused by mutations in any one of hundreds of different genes, making optogenetic therapy a particularly suitable approach as it can potentially help regardless of the underlying mutation.

Safe to use

In the study, 10 participants with blindness due to advanced retinitis pigmentosa were injected in their worse-seeing eye with a gene that produces ChrimsonR – a light-sensitive protein with a peak response at around 590 nm (amber). The team divided the subjects into three dose-escalation groups, receiving 5.0 x 10¹⁰, 1.5 x 10¹¹ or 5.0 x 10¹¹ vector genomes per eye.

The primary aim was to evaluate the safety of the optogenetic therapy. The researchers observed 33 mild and moderate adverse ocular events in nine of the participants, such as temporary inflammation and increases in eye pressure, plus one severe event, which resolved within minutes after treatment. They concluded that, within the limits of the study, the treatment was safe.

Using the light-stimulating goggles, they then assessed the visual performance of treated eyes, before and after injection. The goggles contain a camera that detects changes in light intensities pixel-by-pixel and converts this visual data into pulses of amber light. This light is projected onto the eye to activate ChrimsonR in the modified retinal ganglion cells. Vision tests revealed that the treatment increased light sensitivity in seven of the 10 participants, by a factor of 2.0 to 62.3, with six patients showing a clinically meaningful improvement.

The patients also performed a series of tasks to detect, localize and touch a notebook and a staple-box. In the notebook task, five of eight participants had higher accuracy when wearing the goggles than when not wearing them, while four showed improved accuracy in the staple-box task. In a task determining the orientation of a single bar, accuracy was higher with the goggles in five of eight participants.

To provide an objective measurement of brain activity in response to light, the researchers obtained electroencephalographic (EEG) recordings in five patients performing two visual tests: detection of a tumbler placed in front of them (with the eyes open or closed); and passive viewing of periodic visual stimuli.

In the tumbler test, EEG decoding accuracy was higher with goggles than without when the eyes were open, but not when they were closed – implying a genuine improvement in visual processing rather than an artefact. The second test also showed increased decoding accuracy, which correlated with mean improvements in the notebook and staple-box tasks.

A bright future

The changes in visual performance were consistent across multiple tasks and testing sessions, with responses observed in all three dose groups. Participants who spent longer being trained to use the goggles performed better in the visual behavioural tests. The researchers point out, however, that functional changes were modest: improving object detection and discrimination capabilities but not restoring normal sight. The small sample size also limited their ability to characterize treatment response.

Several projects are currently underway to further enhance the technology. This includes digital holographic goggles with an eye tracker being developed by the team of Valentina Emiliani at the Institut de la Vision in Paris. The system will project 20 µm-wide images that stimulate individual cells in the retina.

“With the eye tracker, we can make sure we are projecting exactly onto the area of the retina that we want. We’ve already developed a prototype, and it is moving forward,” says Sahel.

Elsewhere, University of Pittsburgh scientists are working with Roska’s group to develop cell-specific gene therapy vectors. “There are different types of cells: some respond to the onset of light, some to the offset of light, some to movement and direction,” Sahel explains. “We are trying to selectively stimulate the ‘on’ and the ‘off’, and discriminate the signal we are sending.”

“We are optimistic about advancing this approach toward future clinical trials,” he tells Physics World.

The post Optogenetic therapy shows promise for vision restoration appeared first on Physics World.

The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for “their discoveries concerning light-gated ion channels and optogenetics”.

Optogenetics is a method that uses light to characterize and manipulate the activity of neurons in a living brain. Hegemann and Nagel discovered the light-sensitive protein channelrhodopsin, while Deisseroth transformed the protein into a light-controlled switch for nerve cells.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” says Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine.

From the pond to the brain

Speaking in the press conference following the announcement, neuroscientist Abdel El Manira from the Karolinska Institute described how the breakthrough began with the study of a single-cel­led green alga, Chlamydomonas, known for its ability to swim towards light using a tiny “eyespot” on its surface as a sensor. Hegemann was intrigued as to how this simple organism could transform light into action.

Using electrical measurements to solve this mystery, Hegemann discovered that the eyespot contains a light-sensitive protein that almost instantly converts light into an electrical signal, enabling the alga to move. Hegemann next teamed up with Nagel, who used the gene for Chlamydomona to produce the protein in frog egg cells. They discovered that the protein itself was a light-gated ion channel that opens when exposed to light, allowing positively charged ions to flow into the cell and rapidly generate an electrical signal.

“Nagel and Hegemann realised exactly what they had found. They had just discovered the switch neuroscientists had long dreamed of – a light-gated ion channel they named channelrhodopsin,” says El Manira.

Appreciating the potential of this discovery, Deisseroth – at the time studying ways to establish causal links between specific brain circuits and behaviour – decided to test whether channelrhodopsin could be used as a switch to control the activity of neurons with light. By introducing the DNA encoding the protein (supplied by Nagel) into mammalian neurons and illuminating them with light, he observed a remarkable response: the neurons reacted on command, instantaneously and with millisecond precision.

The real test was whether channelrhodopsin could control neurons in living animals. Deisseroth and colleagues demonstrated that this was possible. By introducing the gene for channelrhodopsin into specific nerve cells in the brains of living mice and illuminating these cells via a thin optic fibre, they activated selected group of neurons and elicited a distinct behaviour.

“For the first time, causal links between specific brain circuits and behaviour had been achieved. The technology, which soon became known as optogenetics, transformed neuroscience,” notes El Manira. “Optogenetics was rapidly and widely adopted all over the world.”

Future medical potential

The field of optogenetics has now enabled researchers to establish causal links between neural activity and behaviour, identifying, for instance, neural circuits associated with pain, social behaviours, thirst, food consumption, reward and attention. Beyond the healthy brain, the technique also sheds light on how specific brain circuits can be disrupted and how this impacts psychiatric and neurological conditions.

And while optogenetics is primarily a tool for basic research and understanding of disease, optogenetic therapy is also showing early promise as a medical treatment. In particular, a landmark study has demonstrated partial recovery of visual function in a blind patient with retinitis pigmentosa, by insertion of a channelrhodopsin-like protein in their retina.

“In this disorder, retinitis pigmentosa, patients lose their photoreceptors, the rods and cones in the retina,” explains Svenningsson. “But there are still healthy cells in the retina and researchers have used optogenetics to stimulate these healthy cells and thereby activate the optic nerve and generate vision perception in the brain. This has been done and there are several clinical trials ongoing with this approach.”

Elsewhere, optogenetics is also under investigation for applications including control of spinal cord activity and bladder activity in small animals, inhibition of nerve pain and guidance of morphogenesis in a living embryo.

Friends together

Karl Deisseroth was born in 1971 and received his PhD and MD from Stanford University in the US, where he performed the work for which he was awarded the prize. He is currently an investigator at the Howard Hughes Medical Institute and professor at Stanford University.

Peter Hegemann was born in 1954 and received his PhD at the Max-Planck-Institute for Biochemistry in Martinsried, Germany, where he made his prize-awarded discoveries. He is now a senior professor of neuroscience at Humboldt University of Berlin, Germany.

Georg Nagel was born in 1953 and received his PhD at the University of Frankfurt, Germany. His prize awarded discoveries were made at Max Planck Institute for Biophysics in Frankfurt. He is currently professor of molecular plant physiology at the University of Würzburg, Germany.

Thomas Perlmann, secretary-general of the Nobel Assembly, described his call to the laureates earlier this morning: “All three were very surprised and all three said the same thing, that it was absolutely wonderful to receive the prize with the other two, called them ‘my friends’, and that it was such an honour to receive them together”.

• Read about the use of organic dyes in optogenetics, in a book chapter co-authored by Peter Hegemann, now free to read on IOP Science.

The post Inventors of optogenetics win Nobel Prize in Physiology or Medicine appeared first on Physics World.